Heron Therapeutics, Inc. reported earnings results for the full year ended December 31, 2023. For the full year, the company reported net loss was USD 110.56 million compared to USD 182.02 million a year ago. Basic loss per share from continuing operations was USD 0.8 compared to USD 1.67 a year ago.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
2.45 USD | -3.92% | -7.20% | +44.12% |
Apr. 23 | Capital One Starts Heron Therapeutics With Overweight Rating, $6 Price Target | MT |
Mar. 21 | Heron Therapeutics, Inc. Announces Executive Changes, Effective March 29, 2024 | CI |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+44.12% | 368M | |
+1.51% | 42.75B | |
+49.22% | 41.61B | |
+8.57% | 41.34B | |
-12.36% | 26.59B | |
+8.92% | 25.49B | |
-25.13% | 18.12B | |
+29.17% | 12.24B | |
-3.12% | 11.76B | |
+6.35% | 11B |
- Stock Market
- Equities
- HRTX Stock
- News Heron Therapeutics, Inc.
- Heron Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023